These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 28710714)

  • 1. Disseminated tumor cells are not associated with established risk factors, L1CAM immunoreactivity and outcome in endometrial carcinoma.
    Kommoss S; Hartkopf AD; Krämer B; Bunz AK; Grevenkamp F; Kommoss F; Pasternak J; Arbabi SM; Wallwiener M; Staebler A; Lax SF; Brucker SY; Taran FA
    J Cancer Res Clin Oncol; 2017 Nov; 143(11):2183-2188. PubMed ID: 28710714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. L1 Cell Adhesion Molecule (L1CAM) expression in endometrioid endometrial carcinomas: A possible pre-operative surrogate of lymph vascular space invasion.
    de Freitas D; Aguiar FN; Anton C; Bacchi CE; Carvalho JP; Carvalho FM
    PLoS One; 2018; 13(12):e0209294. PubMed ID: 30557309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. L1CAM: amending the "low-risk" category in endometrial carcinoma.
    Kommoss F; Kommoss F; Grevenkamp F; Bunz AK; Taran FA; Fend F; Brucker SY; Wallwiener D; Schönfisch B; Greif K; Lax S; Staebler A; Kommoss S
    J Cancer Res Clin Oncol; 2017 Feb; 143(2):255-262. PubMed ID: 27695947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L1CAM Expression is Related to Non-Endometrioid Histology, and Prognostic for Poor Outcome in Endometrioid Endometrial Carcinoma.
    Geels YP; Pijnenborg JM; Gordon BB; Fogel M; Altevogt P; Masadah R; Bulten J; van Kempen LC; Massuger LF
    Pathol Oncol Res; 2016 Oct; 22(4):863-8. PubMed ID: 26891628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. L1CAM expression in endometrial carcinomas: an ENITEC collaboration study.
    van der Putten LJ; Visser NC; van de Vijver K; Santacana M; Bronsert P; Bulten J; Hirschfeld M; Colas E; Gil-Moreno A; Garcia A; Mancebo G; Alameda F; Trovik J; Kopperud RK; Huvila J; Schrauwen S; Koskas M; Walker F; Weinberger V; Minar L; Jandakova E; Snijders MP; van den Berg-van Erp S; Matias-Guiu X; Salvesen HB; Amant F; Massuger LF; Pijnenborg JM
    Br J Cancer; 2016 Sep; 115(6):716-24. PubMed ID: 27505134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results.
    Bosse T; Nout RA; Stelloo E; Dreef E; Nijman HW; Jürgenliemk-Schulz IM; Jobsen JJ; Creutzberg CL; Smit VT
    Eur J Cancer; 2014 Oct; 50(15):2602-10. PubMed ID: 25126672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disseminated tumor cells in bone marrow may affect prognosis of patients with gynecologic malignancies.
    Banys M; Solomayer EF; Becker S; Krawczyk N; Gardanis K; Staebler A; Neubauer H; Wallwiener D; Fehm T
    Int J Gynecol Cancer; 2009 Jul; 19(5):948-52. PubMed ID: 19574790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphovascular space invasion in microcystic elongated and fragmented (MELF)-pattern well-differentiated endometrioid adenocarcinoma is associated with a higher rate of lymph node metastasis.
    Hertel JD; Huettner PC; Pfeifer JD
    Int J Gynecol Pathol; 2014 Mar; 33(2):127-34. PubMed ID: 24487466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of prognostic potential of β-catenin and L1CAM expression according to endometrial cancer risk group.
    Yoon H; Suh DH; Kim K; No JH; Kim YB; Kim H
    Gynecol Oncol; 2024 May; 184():132-138. PubMed ID: 38309030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Microcystic, elongated and fragmented invasion pattern in endometrial carcinoma: the clinicopathology analysis].
    Zhang XB; Zhao CL; Qi XL; Qin Y; Wang Y; Shen DH
    Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):811-815. PubMed ID: 30585018
    [No Abstract]   [Full Text] [Related]  

  • 11. Detection of disseminated tumor cells in patients with gynecological cancers.
    Fehm T; Becker S; Bachmann C; Beck V; Gebauer G; Banys M; Wallwiener D; Solomayer EF
    Gynecol Oncol; 2006 Dec; 103(3):942-7. PubMed ID: 16889820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association of the microcystic, elongated and fragmented (MELF) invasion pattern in endometrial carcinomas with deep myometrial invasion, lymphovascular space invasion and lymph node metastasis.
    Dogan Altunpulluk M; Kir G; Topal CS; Cetiner H; Gocmen A
    J Obstet Gynaecol; 2015 May; 35(4):397-402. PubMed ID: 25279582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endometrioid endometrial carcinomas with microcystic, elongated, and fragmented (MELF) type of myoinvasion: role of immunohistochemistry in the detection of occult lymph node metastases and their clinical significance.
    Espinosa I; Serrat N; Zannoni GF; Rovira R; D'Angelo E; Prat J
    Hum Pathol; 2017 Dec; 70():6-13. PubMed ID: 28601659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative Risk Stratification of Endometrial Carcinoma: L1CAM as a Biomarker.
    Pasanen A; Loukovaara M; Tuomi T; Bützow R
    Int J Gynecol Cancer; 2017 Sep; 27(7):1318-1324. PubMed ID: 29059097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study.
    van der Putten LJM; Visser NCM; van de Vijver K; Santacana M; Bronsert P; Bulten J; Hirschfeld M; Colas E; Gil-Moreno A; Garcia A; Mancebo G; Alameda F; Trovik J; Kopperud RK; Huvila J; Schrauwen S; Koskas M; Walker F; Weinberger V; Minar L; Jandakova E; Snijders MPLM; van den Berg-van Erp S; Matias-Guiu X; Salvesen HB; Werner HMJ; Amant F; Massuger LFAG; Pijnenborg JMA
    Int J Gynecol Cancer; 2018 Mar; 28(3):514-523. PubMed ID: 29324536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. L1 Cell Adhesion Molecule as a Predictor of Disease-Specific Survival and Patterns of Relapse in Endometrial Cancer.
    Pasanen A; Tuomi T; Isola J; Staff S; Bützow R; Loukovaara M
    Int J Gynecol Cancer; 2016 Oct; 26(8):1465-71. PubMed ID: 27648714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer.
    Van Gool IC; Stelloo E; Nout RA; Nijman HW; Edmondson RJ; Church DN; MacKay HJ; Leary A; Powell ME; Mileshkin L; Creutzberg CL; Smit VT; Bosse T
    Mod Pathol; 2016 Feb; 29(2):174-81. PubMed ID: 26743472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Value of β-Catenin and L1CAM Expressions in Type I Endometrial Carcinoma.
    Manule Y; Miskad UA; Masadah R; Nelwan B; Cangara MH; Mardiati M
    Asian Pac J Cancer Prev; 2023 Apr; 24(4):1413-1417. PubMed ID: 37116166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histological features associated with occult lymph node metastasis in FIGO clinical stage I, grade I endometrioid carcinoma.
    Han G; Lim D; Leitao MM; Abu-Rustum NR; Soslow RA
    Histopathology; 2014 Feb; 64(3):389-98. PubMed ID: 24215212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L1CAM expression associates with poor outcome in endometrioid, but not in clear cell ovarian carcinoma.
    Soovares P; Pasanen A; Bützow R; Lassus H
    Gynecol Oncol; 2017 Sep; 146(3):615-622. PubMed ID: 28625395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.